Navigation Links
Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
Date:5/13/2009

FARMINGDALE, N.Y., May 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance at the 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS), which was held in Dallas, TX, April 26-29, 2009, and is widely regarded as the premier educational wound care-focused program in the United States. Also, the SAWC/WHS symposium is the official meeting of the Association for the Advancement of Wound Care (AAWC), a pre-eminent multi-disciplinary organization for wound care. Misonix exhibited and demonstrated its SonicOne(R) Ultrasonic Wound Cleansing and Debridement System to many of the approximately 2,300 clinicians in attendance.

As part of the therapeutic educational program, Oscar Alvarez, Ph.D., FAPWCA, Director of the Center for Curative and Palliative Wound Care at Calvary Hospital, Bronx, NY, and an Associate Professor of Medicine at New York Medical College, presented data on the use of the SonicOne for wound debridement compared to standard "sharps" debridement. Dr. Alvarez's data, for more than 75 patients, with about half of the patients receiving SonicOne treatment and the other half receiving "sharps" treatment, demonstrated statistically significant reductions in the time to healing and the number of debridement procedures when SonicOne was selected as the method of choice.

From humble beginnings in 1988, when a small group of nurses and physicians interested in this emerging discipline created a mission and vision to provide an interdisciplinary forum on wound care, the SAWC/WHS has grown, becoming the largest annual gathering of wound care clinicians in the United States. The SAWC/WHS partnership reflects the need for clinicians to better understand the research and science behind wound management in pursuit of optimal patient outcomes.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased to demonstrate its commitment to the large and rapidly growing wound care market by supporting important educational programs like SAWC/WHS and ASWC," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The wound care product platform, we believe, can make an important contribution to improving patient outcomes and we are gratified when data is presented by clinical experts that support our investment in wound care Research and Development."

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Participation in Annual Diabetic Foot Global Conference
2. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
3. Misonix Announces New HIFU Distribution Agreement For Portugal
4. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
5. Misonix Announces New Distribution Agreement for Portugal
6. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
7. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
8. Misonix Announces New Sales Agency Agreement for Eastern Europe
9. Misonix Announces New Distribution Agreement for Israel
10. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
11. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion ... established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data ... October 1, 2016. , Sarcopenia is defined as a combination of low muscle mass ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... affected by a health insurance co-operative bankruptcy to receive their prescription medications ... receive over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... announced its latest offering, the Protocol Calendar Exchange , is officially open ... pre-built, pre-reviewed protocol calendars available for sites to download into their clinical trial ...
(Date:4/28/2016)... Vail, Colorado (PRWEB) , ... April 28, 2016 ... ... LaPrade, MD, PhD, Chief Medical Officer at the Steadman Philippon Research Institute ... Capitol Hill Day to raise awareness about the debilitating and costly musculoskeletal ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... intelligent business communication applications and infrastructure for telecommunication service providers is pleased ... at Bestel’s Communications Network. The ACONYX Number Portability solution fully meets ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: